Currently Enrolling Trials
Lumigan contains bimatoprost, a synthetic prostamide analog - which acts by mimicking the effects of prostamides, which are naturally occurring substances. It is believed to lower intraocular pressure by increasing the outflow of fluid (known as aqueous humor) produced by the eye.
Lumigan is specifically indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Lumigan is supplied as an ophthalmic solution. Administer one drop in the affected eye(s) once daily in the evening.
Mechanism of Action
Bimatoprost is a prostamide, a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances called prostamides. Bimatoprost is believed to lower IOP in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. (from Lumigan Label)
In clinical trials, adverse events occurring in approximately 15% to 45% of subjects included (but are not limited to) the following:
- Conjunctival hyperemia
- Growth of eyelashes
- Ocular pruritus
Events occurring in approximately 3 to 10% of subjects included those listed below:
- Ocular dryness
- Visual disturbance
- Ocular burning
- Foreign body sensation
- Eye pain
- Pigmentation of the periocular skin
- Eyelash darkening
Clinical Trial Results
Phase III trial results demonstrated that 64% of subjects receiving Lumigan once daily achieved target IOP of less than or equal to 17 mm Hg, whereas 37% of subjects receiving timolol twice daily, a leading drug used to lower IOP, achieved the same target pressure. At six months, Lumigan produced a 33% reduction in IOP compared to 23% with timolol (8.1 mm Hg vs. 5.6 mm Hg, respectively).